Stocktoria

Nuvalent, Inc. NUVL

Nasdaq · stock · Pharmaceutical Preparations · website · IPO 2021-07-29 · LEI

Nuvalent, Inc. financials (annual)

Revenue
202020212022202320242025
Net income
-$14.6M -$46.3M -$81.9M -$126.2M -$260.8M -$425.4M 202020212022202320242025
Free cash flow
202020212022202320242025

Bars are annual figures from 2020 to 2025; red bars are negative (a loss or cash outflow).

MetricFY2025FY2024FY2023FY2022FY2021FY2020
R&D expense$307.0M$217.8M$113.2M$63.7M$35.6M$15.4M
Operating income-$414.3M-$280.4M-$149.5M-$86.1M-$45.8M-$16.9M
Income tax$585,000$764,000$0$0
Net income-$425.4M-$260.8M-$126.2M-$81.9M-$46.3M-$14.6M
EPS (diluted)$-5.85$-3.93$-2.17$-1.65$-2.13$-5.08
Operating cash flow-$275.2M-$185.1M-$99.7M-$65.0M-$40.0M-$14.9M
Cash & equivalents$261.7M$145.7M$335.4M$241.8M$68.5M$10.3M
Total assets$1.4B$1.1B$732.4M$482.5M$293.8M$10.6M
Total liabilities$164.4M$72.0M$31.8M$19.5M$8.8M$6.6M
Shareholders' equity$1.2B$1.1B$700.6M$463.0M$285.0M-$31.3M

Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.